Sign In
Buy VERU
$2.77
+0.440 (+18.88%)
At Close: Aug 10, 2026
Veru Adjourns 2024 Annual Meeting of Shareholders to June 27, 2024
04:05pm, Tuesday, 18'th Jun 2024
MIAMI, FL, June 18, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality
Veru Reminds Shareholders to Vote in Advance of Tomorrow's Deadline for 2024 Annual Meeting of Shareholders
04:45pm, Monday, 17'th Jun 2024
MIAMI, FL, June 17, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality
Veru to Present at the American Diabetes Association's 84th Scientific Sessions
08:30am, Monday, 10'th Jun 2024
MIAMI, FL, June 10, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality
Veru to Present at the Jefferies Global Healthcare Conference
08:30am, Wednesday, 22'nd May 2024
MIAMI, FL, May 22, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality
Veru Announces Steven B. Heymsfield M.D.
08:30am, Wednesday, 15'th May 2024
MIAMI, FL, May 15, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality
Veru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Science & Technology Week
08:30am, Tuesday, 14'th May 2024
MIAMI, FL, May 14, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality
Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical Program
06:30am, Wednesday, 08'th May 2024
--Phase 2b clinical study of enobosarm in combination with semaglutide (Wegovy ® * ) for high quality weight loss is actively enrolling-- --Company assembles esteemed high quality weight loss Scienti
Veru to Present at the GLP-1 Based Therapeutics Summit
08:30am, Thursday, 02'nd May 2024
MIAMI, FL, May 02, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality
Veru to Report Fiscal 2024 Second Quarter Financial Results on May 8, 2024
08:30am, Wednesday, 01'st May 2024
MIAMI, FL, May 01, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality
Veru Inc. (VERU) Just Flashed Golden Cross Signal: Do You Buy?
10:56am, Tuesday, 30'th Apr 2024
Veru Inc. (VERU) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, VERU's 50-day simple moving average crossed above its 200-da
Veru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
08:30am, Tuesday, 30'th Apr 2024
-- The Phase 2b study planned to be conducted in 15 clinical sites in the United States -- -- Topline clinical data expected in the fourth quarter calendar year 2024 --
Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11
08:30am, Thursday, 25'th Apr 2024
MIAMI, FL, April 25, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high qualit
What Makes Veru (VERU) a New Buy Stock
01:01pm, Wednesday, 17'th Apr 2024
Veru (VERU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Veru Reschedules Annual Meeting of Shareholders
04:05pm, Friday, 22'nd Mar 2024
--Restated historical financial statements expected to be filed no later than April 15, 2024-- --2024 Annual Meeting of Shareholders to follow financial statements filings--
Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss
08:00am, Tuesday, 12'th Mar 2024
MIAMI, March 12, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality we
